Proposition

3BP is commercializing three aspects of its technology platform:

  • Out-licensing of therapeutic and diagnostic product candidates after preclinical or clinical proof-of concept
  • Running collaborative peptidomimetics drug discovery programs from hit to preclinical candidate together with pharmaceutical partners
  • Custom development of affinity purification steps based on 3BP's peptidomimetic affinity ligand (PurAffinTM) technology for protein downstream processing
Experts in peptide drug discovery. Ingenuity from concept to clinical candidate.